Liberty Mutual Group Asset Management Inc. bought a new stake in Astrazeneca PLC (NYSE:AZN) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 28,567 shares of the company’s stock, valued at approximately $890,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. Tompkins Financial Corp raised its stake in shares of Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock worth $100,000 after buying an additional 1,422 shares during the period. Pacad Investment Ltd. purchased a new position in Astrazeneca PLC during the fourth quarter valued at about $115,000. Quadrant Capital Group LLC increased its position in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock worth $138,000 after buying an additional 2,805 shares during the period. CENTRAL TRUST Co increased its position in Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock worth $140,000 after buying an additional 91 shares during the period. Finally, Clean Yield Group acquired a new stake in shares of Astrazeneca PLC during the first quarter valued at approximately $184,000. Institutional investors own 14.01% of the company’s stock.
Astrazeneca PLC (NYSE AZN) traded up 0.47% during mid-day trading on Friday, hitting $34.05. 3,602,670 shares of the company’s stock were exchanged. The stock has a market cap of $86.20 billion, a PE ratio of 25.51 and a beta of 0.77. The stock’s 50 day moving average price is $34.22 and its 200-day moving average price is $31.14. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, April 27th. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.38 by $0.61. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. The firm had revenue of $5.41 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the previous year, the firm earned $0.95 earnings per share. The company’s quarterly revenue was down 11.6% compared to the same quarter last year. Equities analysts expect that Astrazeneca PLC will post $1.85 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Liberty Mutual Group Asset Management Inc. Acquires Shares of 28,567 Astrazeneca PLC (AZN)” was first reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/07/23/liberty-mutual-group-asset-management-inc-takes-position-in-astrazeneca-plc-azn-updated-updated.html.
AZN has been the subject of a number of research reports. UBS AG cut Astrazeneca PLC from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.44 to $25.55 in a report on Wednesday, April 5th. BidaskClub cut Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Zacks Investment Research cut Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Finally, Jefferies Group LLC restated a “hold” rating on shares of Astrazeneca PLC in a report on Monday, April 10th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $34.13.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrazeneca PLC and related companies with MarketBeat.com’s FREE daily email newsletter.